Dynavax Technologies Corp (DVAX)
11.25
-0.17
(-1.49%)
USD |
NASDAQ |
Apr 25, 13:21
Dynavax Technologies Cash from Financing (TTM): 1.386M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 1.386M |
September 30, 2023 | -0.237M |
June 30, 2023 | 4.826M |
March 31, 2023 | 6.148M |
December 31, 2022 | 19.52M |
September 30, 2022 | 34.19M |
June 30, 2022 | 31.45M |
March 31, 2022 | 33.76M |
December 31, 2021 | 55.78M |
September 30, 2021 | 41.03M |
June 30, 2021 | 37.12M |
March 31, 2021 | 127.26M |
December 31, 2020 | 109.50M |
September 30, 2020 | 109.43M |
June 30, 2020 | 173.76M |
March 31, 2020 | 80.63M |
December 31, 2019 | 154.35M |
September 30, 2019 | 154.36M |
June 30, 2019 | 88.97M |
March 31, 2019 | 88.50M |
December 31, 2018 | 99.07M |
September 30, 2018 | 117.14M |
June 30, 2018 | 198.50M |
March 31, 2018 | 257.28M |
December 31, 2017 | 187.84M |
Date | Value |
---|---|
September 30, 2017 | 169.55M |
June 30, 2017 | 88.22M |
March 31, 2017 | 29.58M |
December 31, 2016 | 0.531M |
September 30, 2016 | 1.047M |
June 30, 2016 | 153.67M |
March 31, 2016 | 174.16M |
December 31, 2015 | 173.96M |
September 30, 2015 | 183.42M |
June 30, 2015 | 30.47M |
March 31, 2015 | 9.971M |
December 31, 2014 | 9.901M |
September 30, 2014 | 125.43M |
June 30, 2014 | 125.45M |
March 31, 2014 | 125.46M |
December 31, 2013 | 125.40M |
September 30, 2013 | -14.07M |
June 30, 2013 | -13.21M |
March 31, 2013 | 56.80M |
December 31, 2012 | 59.04M |
September 30, 2012 | 140.27M |
June 30, 2012 | 144.13M |
March 31, 2012 | 92.75M |
December 31, 2011 | 91.44M |
September 30, 2011 | 67.75M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.237M
Minimum
Sep 2023
173.76M
Maximum
Jun 2020
66.49M
Average
41.03M
Median
Sep 2021
Cash from Financing (TTM) Benchmarks
Supernus Pharmaceuticals Inc | -397.88M |
Ligand Pharmaceuticals Inc | -59.95M |
Pacira BioSciences Inc | -183.03M |
Esperion Therapeutics Inc | 50.46M |
PetIQ Inc | -10.19M |